Table 1
Active CAR trials for acute leukemias as of September 2013
N/A indicates not applicable.
*Post-allo-HSCT trials harvest T cells from the donor for transduction. Patients with recurrent B-ALL after allo-HSCT are also eligible for several of the trials targeting refractory B-ALL; however, T cells are harvested from the patient and then transduced.